MTA-Uncompetitive PRMT5 Inhibitors for MTAP-Deleted Cancer Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PRMT5 inhibitors lack selectivity for MTAP-deleted cancer cells due to their mechanisms of action as SAM-uncompetitive or SAM-competitive inhibitors, failing to leverage the accumulation of MTA caused by MTAP deletion, which is a common event in various cancers.
Innovation Solution
Development of a compound that binds to PRMT5 in an MTA-uncompetitive manner, exploiting the accumulation of MTA in MTAP-deleted cells to achieve selective inhibition, thereby targeting cancer cells with loss-of-function mutations or deletion of tumor suppressor genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 inhibitors are developed as SAM-uncompetitive or SAM-competitive inhibitors, then they can effectively inhibit PRMT5 activity, but they lack selectivity for MTAP-deleted cancer cells
Solution Approach 1:
The patent changes the binding mechanism parameter from SAM-competitive or SAM-uncompetitive inhibition to MTA-uncompetitive inhibition. This parameter change allows the inhibitor to exploit the accumulated MTA levels in MTAP-deleted cells, achieving both effective PRMT5 inhibition and selective targeting of MTAP-deleted cancer cells
Solution Approach 2:
The patent uses MTA as an intermediary molecule to achieve selective inhibition. By designing an MTA-uncompetitive inhibitor, the drug requires MTA binding to PRMT5 first, then the inhibitor binds to the MTA-PRMT5 complex. This intermediary mechanism ensures that only cells with accumulated MTA (MTAP-deleted cells) are selectively targeted
2Reliability
If current PRMT5 inhibitors are used, then they can inhibit PRMT5 activity in all cells, but they fail to leverage the accumulation of MTA in MTAP-deleted cells
Solution Approach 1:
The patent converts the harmful collateral deletion of MTAP (which causes MTA accumulation and cellular vulnerability) into a beneficial selective target. By designing MTA-uncompetitive inhibitors, the therapy exploits the MTA accumulation caused by MTAP deletion to achieve selective cancer cell killing while sparing normal cells with intact MTAP
Data Source
AI summary
Compounds are provided according to Formula (I):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.